<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioage Labs, Inc — News on 6ix</title>
<link>https://6ix.com/company/bioage-labs-inc</link>
<description>Latest news and press releases for Bioage Labs, Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioage-labs-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354d5078dffbe2df0e5e53.webp</url>
<title>Bioage Labs, Inc</title>
<link>https://6ix.com/company/bioage-labs-inc</link>
</image>
<item>
<title>BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-reports-positive-phase-1-data-for-bge-102-a-novel-oral-nlrp3-inhibitor-demonstrating-potential-best-in-class-reductions-in-hscrp</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-reports-positive-phase-1-data-for-bge-102-a-novel-oral-nlrp3-inhibitor-demonstrating-potential-best-in-class-reductions-in-hscrp</guid>
<pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
<description>120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and web</description>
</item>
<item>
<title>BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-to-present-at-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-to-present-at-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Mon, 13 Apr 2026 20:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference taking place April 13–16, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, Apr</description>
</item>
<item>
<title>BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-reports-full-year-2025-financial-results-and-provides-business-updates-from-the-fourth-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-reports-full-year-2025-financial-results-and-provides-business-updates-from-the-fourth-quarter-of-2025</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating</description>
</item>
<item>
<title>BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 21:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on T</description>
</item>
<item>
<title>BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bla-for-subcutaneous-formulation-of-leqembir-designated-for-priority-review-in-china-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bla-for-subcutaneous-formulation-of-leqembir-designated-for-priority-review-in-china-1</guid>
<pubDate>Mon, 09 Feb 2026 06:07:00 GMT</pubDate>
<description>BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI), has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The BLA for the subcutaneous formulation was accepted for review by the NMPA in January 2026.</description>
</item>
<item>
<title>BioAge Announces Pricing of Upsized $115.0 Million Public Offering</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-announces-pricing-upsized-115-033000271</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-announces-pricing-upsized-115-033000271</guid>
<pubDate>Thu, 22 Jan 2026 03:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 m</description>
</item>
<item>
<title>BioAge Announces Proposed Public Offering</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-announces-proposed-public-offering-210100883</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-announces-proposed-public-offering-210100883</guid>
<pubDate>Tue, 20 Jan 2026 21:01:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwrite</description>
</item>
<item>
<title>BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-announces-indication-expansion-oral-140000370</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-announces-indication-expansion-oral-140000370</guid>
<pubDate>Tue, 20 Jan 2026 14:00:00 GMT</pubDate>
<description>BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolerability to date in ongoing Phase 1 trial, with robust reductions in key inflammatory biomarkers i</description>
</item>
<item>
<title>BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-announces-additional-positive-interim-140000890</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-announces-additional-positive-interim-140000890</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (<2 mg/L) BGE-102 demonstrated significant reductions in IL-6, a key driver of systemic inflammation and cardiovascular risk, and fibrinogen, an independent predictor of cardiovascular events BGE-102 was well tolerated with a favorabl</description>
</item>
<item>
<title>BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-announces-positive-interim-phase-140000098</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-announces-positive-interim-phase-140000098</guid>
<pubDate>Thu, 04 Dec 2025 14:00:00 GMT</pubDate>
<description>BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticip</description>
</item>
<item>
<title>BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-piper-sandler-213000914</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-piper-sandler-213000914</guid>
<pubDate>Tue, 25 Nov 2025 21:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to p</description>
</item>
<item>
<title>BioAge Labs to Present at Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-jefferies-global-140000764</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-jefferies-global-140000764</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside cha</description>
</item>
<item>
<title>BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-reports-third-quarter-214500484</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-reports-third-quarter-214500484</guid>
<pubDate>Thu, 06 Nov 2025 21:45:00 GMT</pubDate>
<description>First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs targeting 2026 IND submissions EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business</description>
</item>
<item>
<title>HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor</title>
<link>https://6ix.com/company/bioage-labs-inc/news/hitgen-partner-bioage-labs-initiates-phase-1-clinical-study-of-bge-102-a-novel-brain-penetrant-nlrp3-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/hitgen-partner-bioage-labs-initiates-phase-1-clinical-study-of-bge-102-a-novel-brain-penetrant-nlrp3-inhibitor</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology</description>
</item>
<item>
<title>BioAge Labs to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-upcoming-investor-203000729</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-upcoming-investor-203000729</guid>
<pubDate>Wed, 20 Aug 2025 20:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD,</description>
</item>
<item>
<title>BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-announces-first-participant-130000804</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-announces-first-participant-130000804</guid>
<pubDate>Fri, 15 Aug 2025 13:00:00 GMT</pubDate>
<description>First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated robust weight loss in preclinical models, both as monotherapy and in combination with GLP-1 receptor agonists Initial Phase 1 SAD data anticipated by end of 2025, with top-line readout of obesity study by end of 2026 EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWS</description>
</item>
<item>
<title>BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-reports-second-quarter-203000978</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-reports-second-quarter-203000978</guid>
<pubDate>Wed, 06 Aug 2025 20:30:00 GMT</pubDate>
<description>Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery platform through molecular profiling of 17,000+ samples from leading European HUNT Biobank EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeut</description>
</item>
<item>
<title>BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-preclinical-data-220000819</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-present-preclinical-data-220000819</guid>
<pubDate>Sat, 21 Jun 2025 22:00:00 GMT</pubDate>
<description>Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting t</description>
</item>
<item>
<title>BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-labs-expands-drug-discovery-130000872</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-labs-expands-drug-discovery-130000872</guid>
<pubDate>Tue, 17 Jun 2025 13:00:00 GMT</pubDate>
<description>Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by</description>
</item>
<item>
<title>BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates</title>
<link>https://6ix.com/company/bioage-labs-inc/news/bioage-expands-apj-agonist-pipeline-130000703</link>
<guid isPermaLink="true">https://6ix.com/company/bioage-labs-inc/news/bioage-expands-apj-agonist-pipeline-130000703</guid>
<pubDate>Tue, 03 Jun 2025 13:00:00 GMT</pubDate>
<description>Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced advances in its apeli</description>
</item>
</channel>
</rss>